Bringing Nobel Prize winning molecular diagnostics
from lab to PoC and patients
Investment Highlights
Revolution in Point of Care diagnostics – combines laboratory accuracy with OTC convenience
Disruptive market approach – opens previously laboratory-based markets for self-testing
Break-even by 2020 and €100 million revenues by 2022 – exit opportunities for investors
Operating in highly attractive markets – high growth with strong, unmatched diagnostic need
First product launch in 2018 for Sexually Transmitted Disease (STD) – far more in pipeline
Strong management and enthusiastic R&D team – strong industry and academic credentials
Our first product is for STDs – but we can quickly address
any disease detected from DNA or RNA
Sexually Transmitted Disease (STD) diagnostics market 2017
Sexually Transmitted Disease (STD) – 357 million cases annually of most common infections.
New products in our pipeline
Influenza – IVD market €1.9 billion in 2015 and €3.3 billion by 2024 with CAGR 6.4%
Hospital acquired diseases, MRSA – diagnostics market size €0.5 billion, CAGR 11.6%, 53 million infected people
Enteric diseases – IVD market €3.1 billion 2012 and €3.6 billion by 2019 CAGR 2.4 %
Anthrax – the global biodefense against anthrax valued at over €2.0 billion already in 2013
Malaria – 214m new cases worldwide, level of spending €2.5 billion, annual funding €8.7 billion by 2030.
Mycobacterium tuberculosis – 9.6 million new infections
Broadly applicable in other fields – veterinary, food safety, detection of biological threats, contamination
Our first product: we address the shortcomings of STD testing with our revolutionary technology
Accuracy, Convenience and Scalability – platform for future detection of all STD‘s in one test
Why invest into Selfdiagnostics today?
- Proprietary, patented technology – can detect anything with DNA/RNA, highly scalable
- Massive growth potential through broad pipeline in existing and new market segments
- Annual revenues of up to €100 million within five years from proprietary pipeline
- Realistic projections – first market launch in 2018, all R&D milestones were met so far
- Strong management team with complementary mix of startup and industry experience
- Break-even within three years provides attractive first exit opportunity to investors
All inquiries please contact:
Founding CEO – Marko Lehes
+372 521 5105
Skype: mlehes
